Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs J M Smucker Co (SJM) Price & Performance

Amylx Pharmaceuticals IncTrade
J M Smucker CoTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs J M Smucker Co — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while J M Smucker Co trades at $117.46 (market cap $12.54B). The key difference: J M Smucker Co is far larger — about 4.8× Amylx Pharmaceuticals Inc's market cap, and J M Smucker Co pays a 3.82% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXSJM
Market Cap
$2.64B$12.54B
Sector
HealthConsumer Staples
52-Week High
$24.19$126.35
52-Week Low
$7.82$89.53
Enterprise Value
$2.39B$19.57B
Dividend Yield
3.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

J M Smucker Co

SJM trades at $118.79, up 0.61% today, with a bullish technical signal and analyst consensus price target of $125.11. Recent earnings have shown beats in Q4 2025 and Q1 2026, but the company reported a net loss of $1.23B in 2025, with negative profit margins and ROE. Cash flow from operations remains strong at $1.21B, supporting a dividend increase to $1.12 per share, marking 25 consecutive years of growth. The stock is supported by positive media coverage highlighting value and growth potential.

The outlook is mixed; strong cash flow and dividend growth provide stability, but profitability challenges and high debt levels pose risks. Analyst sentiment is predominantly buy-rated, suggesting upside potential, though investors must weigh fundamental weaknesses against technical and sentiment positives for balanced decision-making.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About J M Smucker Co

J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.

Read more on SJM